Inventor profile of:

Michael Hedvat

City:

Encino, California

Country:

United States

Published Applications:

35

Last publication date:

2026-05-14

Top Assignees for applications by Michael Hedvat

The entities that hold a legal rights for patent applications filed by inventor Hedvat Michael:

Recent patent applications by Hedvat Michael

Michael Hedvat from Encino, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-05-14
US20260132202A1
Chemistry; metallurgy

BISPECIFIC ANTIBODIES THAT BIND PD-L1 AND CD28

#2 | 2025-12-25
US20250388704A1
Chemistry; metallurgy

ANTI-CD28 X ANTI-PSMA ANTIBODIES

#3 | 2025-10-30
US20250333519A1
Chemistry; metallurgy

BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIES

#4 | 2025-04-17
US20250122299A1
Chemistry; metallurgy

ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES

#5 | 2025-02-06
US20250043001A1
Chemistry; metallurgy

ANTI-CD28 COMPOSITIONS

#6 | 2024-12-19
US20240417466A1
Chemistry; metallurgy

HETERODIMERIC ANTIBODIES THAT BIND PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND CD3

#7 | 2024-08-22
US20240279356A1
Chemistry; metallurgy

HETERODIMERIC ANTIBODIES THAT BIND MSLN AND CD3

#8 | 2024-07-04
US20240218082A1
Chemistry; metallurgy

ANTI-CD28 X ANTI-PSMA ANTIBODIES

#9 | 2024-02-22
US20240059786A1
Chemistry; metallurgy

ANTI-CD28 X ANTI-TROP2 ANTIBODIES

#10 | 2024-01-25
US20240026002A1
Chemistry; metallurgy

BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS

#11 | 2023-11-30
US20230383012A1
Chemistry; metallurgy

ANTIBODIES THAT BIND PD-L1, PD-L2, AND/OR CD28

#12 | 2023-10-26
US20230340128A1
Chemistry; metallurgy

ANTI-CD28 X ANTI-MSLN ANTIBODIES

#13 | 2023-10-12
US20230322961A1
Chemistry; metallurgy

ANTI-CD28 X ANTI-PSMA ANTIBODIES

#14 | 2023-08-24
US20230265218A1
Chemistry; metallurgy

ANTI-CD28 X ANTI-PSMA ANTIBODIES

#15 | 2023-08-17
US20230257466A1
Chemistry; metallurgy

ANTI-CD28 COMPOSITIONS

#16 | 2023-02-23
US20230055445A1
Chemistry; metallurgy

PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS AND USES IN COMBINATION THERAPIES THEREOF

#17 | 2023-02-09
US20230041377A1
Chemistry; metallurgy

BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIES

#18 | 2022-06-30
US20220204624A1
Chemistry; metallurgy

Bispecific and monospecific antibodies using novel anti-PD-1 sequences

#19 | 2022-05-05
US20220135684A1
Chemistry; metallurgy

BISPECIFIC ANTIBODIES THAT BIND PD-L1 AND CD28

#20 | 2022-04-21
US20220119530A1
Chemistry; metallurgy

Anti-CD28 compositions

#21 | 2022-04-21
US20220119525A1
Chemistry; metallurgy

Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3

#22 | 2022-04-07
US20220106403A1
Chemistry; metallurgy

HETERODIMERIC ANTIBODIES THAT BIND MSLN AND CD3

#23 | 2022-03-31
US20220098306A1
Chemistry; metallurgy

Anti-CD28 compositions

#24 | 2021-11-18
US20210355185A1
Chemistry; metallurgy

Targeted IL-12 heterodimeric Fc-fusion proteins

#25 | 2021-08-19
US20210253706A1
Chemistry; metallurgy

BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS

#26 | 2021-06-10
US20210171596A1
Chemistry; metallurgy

Untargeted and targeted IL-10 Fc-fusion proteins

#27 | 2021-04-01
US20210095030A1
Chemistry; metallurgy

BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS

#28 | 2020-05-07
US20200140512A1
Chemistry; metallurgy

PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof

#29 | 2019-12-26
US20190389954A1
Chemistry; metallurgy

Bispecific checkpoint inhibitor antibodies

#30 | 2019-12-19
US20190382495A1
Chemistry; metallurgy

Bispecific checkpoint inhibitor antibodies

#31 | 2019-09-05
US20190270816A1
Chemistry; metallurgy

Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

#32 | 2019-08-29
US20190263909A1
Chemistry; metallurgy

Bispecific and monospecific antibodies using novel anti-PD-1 sequences

#33 | 2018-05-10
US20180127501A1
Chemistry; metallurgy

Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

#34 | 2018-05-03
US20180118836A1
Chemistry; metallurgy

Bispecific checkpoint inhibitor antibodies

#35 | 2007-05-10
US20070104714A1
Human necessities

Composition and method for the treatment of cancer and other physiologic conditins based on modulation of the ppar-gamma pathway and her-kinase axis

InventorID:

2184029 ⎘